Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-02-26 | Direct | 70,000 |
Reported balance
After 2021-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-26 · Grant · Acquired 70,000 · Balance 70,000 F1: The option was granted on February 26, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on February 26, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-02-28 | Direct | 91,096 |
Reported balance
After 2021-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-28 · Grant · Acquired 21,096 · Balance 91,096 F2: The option was granted on February 28, 2021 and represents a pro rata amount of the annual 25,000 option board grant based on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on February 26, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on February 26, 2022.
F2: The option was granted on February 28, 2021 and represents a pro rata amount of the annual 25,000 option board grant based on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2021 Filed Mar 2, 2021 22:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 21,096 | $6.77 Strike: $6.77 | $142,819.92 |
DisclosureSEC source: 0000921895-21-000601 · form412566002_03022021.xml · derivative · entry 2 Wang Luhua · CIK 0001847910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,096 Underlying: Common Stock · 21,096 shares Expires 2031-02-28 F2 · derivative.exercise_date: The option was granted on February 28, 2021 and represents a pro rata amount of the annual 25,000 option board grant based on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:36 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 70,000 | $6.77 Strike: $6.77 | $473,900.00 |
DisclosureSEC source: 0000921895-21-000601 · form412566002_03022021.xml · derivative · entry 1 Wang Luhua · CIK 0001847910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-02-26 F1 · derivative.exercise_date: The option was granted on February 26, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on February 26, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.